News - Zaltrap, Avastin

Filter

Current filters:

ZaltrapAvastin

Popular Filters

1 to 25 of 74 results

NICE final guidance again rejects Sanofi’s Zaltrap for colorectal cancer

25-03-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE), today issued final guidance…

Northern EuropeOncologyPharmaceuticalPricingRegulationSanofiUKZaltrap

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

06-03-2014

Swiss pharma majors Roche and Novartis colluded to exclude the cheaper cancer drug Avastin (bevacizumab),…

AvastinEuropeFinancialItalyLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Avastin seen to prolong life for women with advanced cervical cancer

Avastin seen to prolong life for women with advanced cervical cancer

20-02-2014

Swiss drug major Roche’s blockbuster cancer drug Avastin (bevacizumab) can extend the lives of women…

AvastinOncologyPharmaceuticalResearchRoche

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

BIA warns that UK government pricing proposals would damage UK biotech

20-08-2013

The BioIndustry Association (BIA), the UK trade association for the innovative biotechnology sector,…

AvastinBayerEuropeEyleaFinancialLucentisPharmaceuticalPoliticsPricingRegeneronRoche

US firms establish strategic partnership around biosimilars

06-08-2013

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Cheaper anti-cancer drug as effective as expensive disease-specific agent in treating wet AMD

21-07-2013

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness…

AvastinBiotechnologyEuropeFinancialLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

UK's NICE issues negative new draft guidance on Sanofi's Zaltrap

21-06-2013

The UK's drug watchdog the National Institute for Health Care and Excellence (NICE) has issued new draft…

EuropeOncologyPharmaceuticalPricingRegulationSanofiZaltrap

Additional indications in Japan for Roche's Avastin and Astellas' Prograf

17-06-2013

Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

Roche's Avastin extends lives of cervical cancer patients; positive in glioblastoma

03-06-2013

Data presented from the study, known as GOG240, showed that the addition of Swiss pharma major Roche's…

AvastinBiotechnologyGenentechOncologyPharmaceuticalResearchRoche

NICE rejects Avastin for ovarian cancer, but backs Lucentis for RVO

22-05-2013

The UK's drugs watchdog the National Institute for Health and Care Excellence (NICE) has this morning…

AvastinBiotechnologyEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPricingRegulationRoche

Should medical compendia hold so much power? Asks GlobalData

10-04-2013

Guidelines for off-label drug use hold immense commercial implications, and stricter controls are needed…

AvastinBiotechnologyNorth AmericaOncologyPharmaceuticalRegulation

UK's NICE draft guidance says "no" to Roche's Avastin for ovarian cancer

25-03-2013

New, draft guidance issued today (March 25) by the UK's drugs watchdog the National Institute for Health…

AvastinOncologyPharmaceuticalPricingRegulationRoche

Russia's Biocad plans to produce high-tech drugs in Brazil

19-03-2013

Biocad, one of Russia's leading biotechnology companies, plans to launch production of several of its…

AvastinBiocadBiotechnologyGenericsHerceptinMabTheraOncologyProductionRocheSouth America

Italy's antitrust body investigating Roche and Novartis for alleged cartel

21-02-2013

The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…

AvastinBiotechnologyEuropeGenentechLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

1 to 25 of 74 results

Back to top